A collaboration of the #HIRI, Akribion Therapeutics, @utah.edu and @utahstate.bsky.social has now resulted in a CRISPR-based tool that can target specific cells based on a recognized transcript, opening up numerous potential uses. Read more: www.helmholtz-hiri.de/en/newsroom/...